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Abstract
Cancer cells can develop an attenuated immunogenicity and/or create an immunosuppressive microenvironment to
prevent tumor eradication by host immune system, the so-called “cancer immunoediting” hypothesis. The aim of the
present studywas to find evidence for this hypothesis by using a rat orthotopic bladder cancermodel. Fisher ratswere
inoculated with AY-27 cells (a Fisher rat bladder cancer cell line). Cultured cancer cells, rat and human bladder cancer
tissues, and publicly available microarray data from human bladder cancer were analyzed by means of bioinformatics
and morphology. Results showed that 12 of 24 differentially expressed pathways were concordant in connection to
cell cycle and proliferation between rats and humans (both non–muscle-invasive andmuscle-invasive tumors) and that
11 of the 24 pathways, including major histocompatibility complex, were related to host immunosurveillance with
activations of T cells and natural killer cells in rats. The altered pathways and morphogenesis of this rat model corre-
sponded more closely with those of human muscle-invasive rather than non–muscle-invasive tumors. A unique ultra-
structure displaying microvillus-formed niches was found in small areas within the tumor of both rats and humans.
These niches were interconnected with desmosomes between cancer cells and without infiltration of lymphocytes.
The expression of E-cadherin, selectins, PGP9.5, vascular endothelial growth factor, caspase-3, CD133, Oct-4, nestin,
CD3, and CD45RA was lower in the tumor than in the adjacent normal epithelium. We suggest that the microvillus-
formed niche that harbors a few implanted cancer cellsmight be the compartment that prevents the tumor eradication
by the host immune system.
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Introduction
Ideal animal cancer models should, in principle, reflect tumor biology
in humans. Like humans, immunocompetent animals are capable of
recognizing and eliminating syngeneic cancer cells not only before
the development of a tumor but also after tumor formation, the so-
called “cancer immunosurveillance” [1,2]. However, tumors in im-
munocompetent individuals still occur and progress, which is called
tumor immunoescape. Conceivably, cancer cells (most likely a sub-
population of the cancer cells) can develop an attenuated immuno-
genicity and/or create an immunosuppressive tumor microenvironment
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that effectively prevents tumor eradication by the host immune system,
called “cancer immunoediting” [3,4].
Recently, we have shown that the host immune system was fully
active in the form of immunosurveillance, and yet, the tumors still
progressed in a syngeneic orthotopic rat bladder cancer model [5].
Moreover, this syngeneic orthotopic bladder cancer model showed a
similar but more rapid progression compared with chemical carcinogen
N -butyl-N -(4-hydroxybutyl)nitrosamine (BBN)–induced bladder
cancer model [5,6] (own unpublished data). A recent study also showed
that BBN-induced rodent (mouse and rat) models of bladder cancer
shared genetic similarities with pathways relevant to the development
of muscle-invasive bladder cancer in humans [7]. In the present study,
we wanted to test the cancer immunoediting hypothesis by using the
syngeneic orthotopic rat bladder cancer model in comparison with
human bladder cancer. First, we sought the gene expression profile
for immunoediting by gene expression profiling and pathway analysis
in comparisons between rat bladder cancer cells in vitro (AY-27 cell line)
and in vivo and between the rat and human bladder cancers. Second, we
sought morphological evidence for the immunosuppressive microenvi-
ronment in both rat and human bladder cancers by transmission elec-
tron microscopy and immunohistochemistry.
Materials and Methods
Bladder Cancer Cells and Syngeneic, Orthotopic Bladder
Cancer Model
A syngeneic rat bladder cancer cell line (AY-27) was originally estab-
lished as a primary bladder cancer developed in Fischer 344 rats ex-
posed to N -[4-(5-nitro-2-furyl)-2-thiazolyl]formamide) and was
kindly provided by Prof S. Selman, Department of Urology, Medical
College of Ohio. The cells were cultivated on culture dishes with six
wells in Dulbecco’s modified Eagle medium (Sigma, St Louis, MO),
10% fetal bovine (Sigma), 1% penicillin-streptomycin (5000 U/ml
of penicillin-G and 5 mg/ml of streptomycin; Sigma); and 0.5%
L-glutamine (Sigma). For trypsinization, trypsin-EDTA solution
(Sigma) was used. The cells were maintained in an incubator in a hu-
mid environment at 37°C and 5% CO2. Doubling time of the AY-27
cells in the pure culture was 27 hours (E. Larimar and D. Chen, un-
published data).
An orthotopic rat bladder cancer model has been described previ-
ously [8]. In the present study, female Fisher inbred rats (2-month-
old F344; Möllegaard, Skensved, Denmark) were used. The animals
were housed in plastic cages with hardwood chips at room temperature
of 22 ± 1°C, humidity of 45% to 55%, and 12 hours of light/dark
cycle. Microbiological status was conventional and pathogen-free.
The animals had free access to commercial standard rat food pellets
(RM1; Scanbur BK AS, Karlslunde, Denmark) and tap water. For es-
tablishing bladder cancer, the animals were anesthetized by subcutane-
ous injection of 0.02 ml/kg of a solution containing 2.5 mg/ml
fluanisone, 0.05 mg/ml fentanyl, and 1.25 mg/ml midazolam (Hyp-
norm [ Janssen Animal Health, Buckinghamshire, UK] or Dormicum
[Alpharma AS, Oslo, Norway]). The amount of 4.0 × 105 AY-27 cells
per rat was inoculated with an 18-gauge plastic intravenous cannula. A
series of rats were subjected to intravesicle bladder cancer cell inocula-
tion and killed at 1, 2, and 3 weeks (three to nine rats at each time
point), respectively. A group of nine age- and sex-matched normal rats
was used as controls. Entire bladders from six rats at the time point of
2 weeks after inoculation together with entire bladders from six controls
were additionally used for microarray analysis. Approval for the experi-
ments was obtained from the Norwegian Animal Research Authority.
Human Bladder Cancer Patients
Three patients whose conditions were diagnosed as muscle-invasive
urothelial cancer (grade 3 according to the World Health Organization)
underwent radical cystectomy at StOlav’sUniversityHospital, Trondheim,
Norway. Immediately after the bladder was removed, several small tis-
sue specimens (1 × 1 × 1 m3) were taken from defined tumor areas and
immersed in a fixative for electron microscopic analysis (see below). Ap-
proval for the analysis was obtained from the local ethics committee and
from the patients.
Morphological Analysis
The cultured cells and the bladder tissue samples from both rats and
patients were collected for both light and transmission electron micro-
scopic evaluations. In brief, the tissue samples were immersed in 4%
formaldehyde for 8 to 12 hours at 4°C, dehydrated and embedded in
paraffin blocks, and cut at a 4-μm thickness through the whole blad-
der. Every fifth section was thawed onto glass slides and subjected to
a routine hematoxylin-eosin-safron staining for evaluation under a
microscope (Nikon Eclipse 55i; Instrument AB, Oslo, Norway). For
immunohistochemistry, the tissue sections (from the rats only) were
treated with 3% H2O2 to quench endogenous peroxidase, washed sev-
eral times, and blocked with 10% normal goat serum. The sections
were incubated with a series of primary antisera for 48 hours at 4°C
(Table 1). Afterward, the sections were incubated in biotinylated anti-
rabbit or antimouse immunoglobulin G for 1 hour (Envision Kit K4007
or K4011; Dako, Glostrup, Denmark). After several washes in Tris-
buffered saline, sections were incubated in 0.05% diaminobenzidine/
0.001%H2O2 solution and washed at least two times with Tris-buffered
saline. Sections were counterstained, dehydrated with absolute alcohol
followed by xylene, coverslipped with Permount (The Science Com-
pany, Denver, CO), and examined under a microscope (Nikon).
For electron microscopy, many small tissue specimens were taken
from different sites of the rat bladder and defined tumor sites of the
patient’s bladders and were immediately immersed in a mixture of 2%
glutaraldehyde in 0.1MPBS, pH7.2. After 6 hours, the specimens were
transferred to 1%OsO4 and postfixed for 1 hour, dehydrated in graded
acetone, and embedded in Epoxy (TAAB Laboratories, Berkshire, UK).
Ultrathin sections of 60- to 80-nm thickness were cut on an LKB MK
III Ultratome (LKB, Bromma, Sweden), contrasted with uranyl acetate
and lead citrate, and examined under a transmission electronmicroscope
( Joel, Tokyo, Japan).
Complementary DNA Microarray and Data Analysis
Cultured AY-27 cells and the entire bladder from each rat were taken
and immediately frozen in a bath of liquid nitrogen and stored at −80°C
until isolation of RNA using the RNeasy Fibrous Midi Kit and RNase-
free DNase Set (Qiagen, Valencia, CA). Isolated RNA was analyzed by
Affymetrix GeneChip (Affymetrix, Santa Clara, CA) with a RAE 230 A
chip that includes more than 15,000 rat genes. The arrays were scanned
using Affymetrix GeneChip Scanner 3000 7G controlled by GCOS
1.3. Data were normalized using robust multiarray averaging, and data
quality was evaluated by principal component analysis (PCA). Differ-
entially expressed genes were identified, P values were corrected for
multiple testing, and genes with P < .05 were taken as significant. Indi-
vidual genes were functionally annotated using EGON v2.0 program
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(NTNU, Trondheim, Norway). Pathway analysis with Kyoto En-
cyclopedia of Genes and Genomes (Kyoto, Japan) was performed. In
addition, publicly available microarray data from human bladder tu-
mors [9] were downloaded from ArrayExpress and normalized using
the same procedure as for the rat data.
Results
Gene Expression Profiling
PCA revealed different gene expression profiles among the normal
bladder, bladder cancer in vivo, and cultured cancer cells (Figure 1, A
and B). In the tissue microenvironment, 69% of differentially ex-
pressed genes were functionally related to cell communication, and
16% of genes were related to cell adhesion. In the cultured cancer
cells, 39% of genes were annotated to cellular process, 34% were an-
notated to cellular physiological process, and 7% to 10% were anno-
tated to cell death, cell cycle, or signal transduction. In the rat bladder
cancer tissue, major histocompatibility complex (MHC I and II) path-
ways involving CD8- and CD4-evoked T cells, and KIR-evoked natu-
ral killer cells were upregulated. It should be noted that most genes in
MHC I and all genes in MHC II were upregulated, and none of the
genes in either MHC I or MHC II was downregulated. T-cell receptor
signaling pathways in CD4 and CD8 T cells and natural killer cell–
mediated cytotoxicity in natural killer cells were activated (Figure 2).
The comparison between this rat model and humans (both non–
muscle-invasive and muscle-invasive tumors) revealed that 12 of 24
differentially expressed pathways were concordant in connection to
cell cycle and proliferation. In the rat model, it was noted that 11
of 24 pathways were related to host immunosurveillance. Moreover,
significantly differentiated pathways of this syngeneic orthotopic rat
bladder cancer model corresponded much more closely with those of
muscle-invasive human tumor (eight pathways) rather than with
those of non–muscle-invasive tumors (four pathways; Table 2).
Figure 1. PCA of gene expression patterns (A) and histological diagnosis (B) of normal bladder (N), bladder cancer (B; 2 weeks after
inoculation of AY-27 cells), and bladder cancer AY-27 cells in culture (C). Note that the gene expression profiles of the normal bladder
and the bladder cancer are distinctly different; however, the magnitude of change is even greater between the bladder cancer and the
cancer cells in panel A. Magnifications are the same as in panel B.
Table 1. List of Primary Antibodies Used for Immunohistochemical Analysis.
Antibody Name Species Immunized Code No. Working Dilution Source Specificity
PCNA Monoclonal M0879 1:100 Dako Primarily with a polypeptide corresponding to PCNA
Caspase-3 Rabbit 9662 1:10 Cell Signaling Full-length caspase-3 (35 kDa) and large fragment of caspase-3
resulting from cleavage (17 kDa)
E-selectin Rabbit Sc14011 1:100 Santa Cruz Amino acids 311-610 mapping at the C-terminus of E-selectin of
human origin
L-selectin Rabbit Sc15331 1:100 Santa Cruz Amino acids 224-372 mapping at the C-terminus of L-selectin of
human origin
P-selectin Rabbit Sc25771 1:100 Santa Cruz Amino acids 651-800 of P-selectin of human origin
E-cadherin Rabbit Ab53226 1:300 Abcam N-terminal region of rat E-cadherin
Desmoglein1 + 2 Monoclonal BM370 1:5, 1:10, or 1:50 Santa Cruz Desmosome-specific cadherins in desmosome-bearing cells
CD133 Rabbit Ab19898 1:100 Abcam C-terminus of human CD133
Nestin Rabbit N5413 1:100 Sigma Residues 254-270 of human nestin, 93% identical to rat nestin
Oct-4 Rabbit Abin223270 1:200 Antibodies-online GmbH N-terminus of mouse Oct-4
VEGF Monoclonal Sc7269 1:100 Santa Cruz Amino acids 1-140 of VEGF of human origin
PGP9.5 Monoclonal Z5116 1:30 Dako A band corresponding to protein gene product 9.5 (PGP9.5)
CD3 Rabbit Ab5690 1:100 Abcam Amino acids 156-168 of human CD3 epsilon chain
CD45RA Monoclonal Ab22363 1:200 Abcam A high–molecular weight band of the leukocyte common antigen
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Morphogenesis of Rat Bladder Cancer and Comparison with
Human Bladder Cancer
Minimal tumor formation was found 1 week after cancer cell inocu-
lation. Inflammation characterized as lymphocyte infiltration was often
observed within the mucosa (Figure 3A). At 2 weeks, carcinoma in situ
and microinvasion into the lamina propria were observed. The tumors
appeared surrounded by lymphocytes. Notably, small blood vessel den-
sity increased in the lamina propria adjacent to but not within the tumor
(Figure 3B). At 3 weeks, both number and size of tumors increased, and
the tumors invaded deeply into the lamina propria. Interestingly, in
some areas, large tumors were noted with only moderate inflammation,
and concurrently, small tumors were surrounded by intensive inflamma-
tory responses (Figure 3,C andD). These histological features were also
found in the human tumors (at stage T2 or 3 with grade 3; Figure 3, E
and F ).
The AY-27 cancer cells in culture had a typical malignant ultrastruc-
ture characterized by irregular, pleomorphic microvilli (Figure 4A).
Three weeks after being inoculated into the bladder, the cancer cells
appeared to be crowded together, had smaller cell profile size, and
had a more undifferentiated appearance than those in the culture
(Figure 4B). Concurrently and very occasionally, a small area of the
tumor was found to display a unique ultrastructure characterized by a
microvillus-formed mesh (Figure 4C ). At higher magnification, the
microvilli were tightly connected to each other by desmosomes (Fig-
ure 4D). Lymphocytes were not observed inside the mesh. In the hu-
man bladder cancer specimens, a similar ultrastructure displaying the
desmosome-connected microvilli was also found (Figure 4, E–H ).
Immunocytochemical Characterization of Rat Bladder Cancer
Figure 5, A–O, shows a panel of immunostained tissue sections of
the bladder cancer versus adjacent normal tissue with the antibodies
to identify markers for the desmosome-connected microvilli, immune
cells, cancer stem cells (CSCs), and stem cells in general. As expected,
the cell proliferation marker proliferation cell nuclear antigen (PCNA)
was increased, and the apoptosis marker caspase-3 was reduced in the
tumor area. However, E-cadherin, one of cadherins of the desmosomes,
and selectins (including E-, L-, and P-selectins) were found to be ex-
pressed in the normal epithelia but not in the tumor. Desmoglein1 + 2
was negative in the bladder but positive in other organs (e.g., stomach;
data not shown). Markers of CSCs and/or stem cells, namely, CD133,
Oct-4, and nestin, were positive in normal epithelial cells but slightly
positive or not in the tumors. Vascular endothelial growth factor
(VEGF), a tumor angiogenesis-promoting factor, was found to be less
Figure 2. Diagram showingMHC I and II pathways in the bladder cancer tissue 2 weeks after inoculation. Upregulated genes (P< .01; red)
and unchanged genes (yellow). Note: No downregulated genes.
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expressed in the tumor than in the adjacent normal tissue. Protein gene
product 9.5 (PGP9.5), a tumor suppressor gene protein [10], was
highly expressed in the normal epithelia but absent in the tumor area.
In addition, markers for lymphocytes, namely, CD3 and CD45RA,
were found more in the adjacent areas of the tumor than in the areas
within the tumors.
Discussion
Carcinogenesis involves the interaction between host and tumor cells in
three phases: elimination of tumor cells by host (immunosurveillance),
equilibrium between host and tumor cells, and escape of tumor cells
from host immune response (immunoediting) [1–5,11,12]. In the pres-
ent study, we have found that the microvillus-formed niche that harbors
a few implanted cancer cells might be the compartment that prevents
the tumor eradication by the host immune system.
In the present study, 4.0 × 105 AY-27 cells (approximately 0.5 mm3
in total cell volume with 27 hours of cell doubling time) were inocu-
lated into each rat. Three weeks later, macrotumors (1-5 mm3) were
found. Conceivably, most cancer cells did not survive or were elimi-
nated after implantation by immunosurveillance, a response possibly
mediated by the MHC I and II pathways that are associated with
activations of CD8- and CD4-mediated T cells and KIR-mediated nat-
ural killer cells. Apparently, some of the cancer cells were capable of
escaping from the immunosurveillance, possibly because of the loss
or down-regulation of surface “foreign” antigens within the MHC I
Figure 3. Histopathology of rat (A–D) and human (E–F) bladder cancer. (A) Inflammation with lymphocyte infiltration (indicated by arrow)
within the mucosa and lamina propria 1 week after inoculation. (B) Carcinoma in situ (asterisk) surrounded by lymphocytes 2 weeks after
inoculation. Note also: Many small blood vessels (arrow) in the lamina propria. (C and D) Carcinoma in situ (asterisks) 3 weeks after
inoculation. Lymphocyte aggregations (arrows) in the lamina propria in panel C and surrounding the tumor in panel D. (E and F) Car-
cinoma (asterisks) surrounded and/or infiltrated by lymphocytes (arrows). Hematoxylin-eosin-safron stain: bars, 100 μm (A–D) and 50 μm
(E and F).
Table 2. Pathway Analysis of Orthotopic Rat Bladder Cancer and Human Bladder Cancer at Stage
Ta-T1 (Non–Muscle-Invasive) or T2-T4 (Muscle-Invasive) with Grade > 3.
KEGG Term Rats, P Human (Ta-1), P Human (T2-4), P
Proteasome .000 .934 .007
Antigen processing and presentation* .000 .932 .991
Cell cycle .000 .294 .000
DNA replication .000 .869 .000
Primary immunodeficiency* .001 .691 .968
Systemic lupus erythematosus* .002 .376 .321
Pyrimidine metabolism .002 .286 .017
Graft-versus-host disease* .002 .753 .937
One carbon pool by folate .003 .351 .057
Purine metabolism .003 .007 .007
p53 signaling pathway .006 .054 .004
Natural killer cell–mediated cytotoxicity* .009 .660 .900
Adherens junction .009 .017 .090
Type I diabetes mellitus* .010 .639 .895
Cell adhesion molecules .011 .026 .252
T-cell receptor signaling pathway* .011 .463 .673
Allograft rejection* .014 .856 .968
Thyroid cancer .015 .539 .445
Toll-like receptor signaling pathway* .020 .870 .853
Ubiquitin-mediated proteolysis .022 .984 .789
B-cell receptor signaling pathway* .032 .136 .667
Autoimmune thyroid disease* .035 .968 .997
Small cell lung cancer .036 .149 .010
Amyotrophic lateral sclerosis .042 .434 .816
Significantly differentiated pathways of rats correspond more closely with those of muscle-invasive
than non–muscle-invasive humans.
KEGG indicates Kyoto Encyclopedia of Genes and Genomes.
*Note that host response pathways are revealed in rat and not human tumor tissue. This is prob-
ably because the entire tumor-bearing rat bladder was analyzed as opposed to humans in which
only tumor tissue was analyzed.
438 Bladder Cancer Niche Arum et al. Neoplasia Vol. 12, No. 6, 2010
complex, which “veils” the tumor tissue and, in a sense, makes it “in-
visible” to immune cells [13]. However, we were unable to specifically
identify these cancer cells by immunohistochemistry using currently
available antibodies.
In the present study, we found the differences in gene expression
profiles among the bladder cancer cells in vitro, the in vivo normal
bladder, and the bladder with implanted tumor. It is obvious that the
cellular composition of each of these samples is markedly different.
To take these differences (called different experimental conditions)
into account, we have applied PCA, a statistical technique for deter-
mining the variables in a multidimensional data set. In the present
study, both experimental conditions and genes were considered as
variables. A set of principal gene components (Figure 1A, red, green,
and black) reveals the features of genes that best explain the experi-
mental conditions (Figure 1, A and B: N , B, and C ). Namely, the
bladder cancer (B) is located in a completely different spatial compo-
nent compared with the normal bladder (N) or the cultured cells (C).
If this difference had only been due to the cellular composition of the
experimental conditions, B would be located between N and C. The-
oretically, an artificial mixture of cultured cancer cells and normal
bladder tissue would be located in the area between N and C. It will
be of interest to use laser capture microdissection technique to obtain
pure populations of normal epithelia and tumor cells for the gene
expression profiling. Unfortunately, it is still difficult to dissect the
pure tumor cells because the tumors are heterogeneous, and there
are no available staining markers specifically for the tumor cells.
The fact that the gene expression profile of the bladder cancer differs
from that of the normal bladder and the cultured cancer cells is most
likely due to the interactions between the host and the cancer cells.
Indeed, morphology (including ultrastructure) of the cancer cells in tis-
sue was different from the cancer cells in the culture (Figures 1B and
4), and the bladder with cancer had a high degree of inflammation (see
also Figures 1B and 3). The difference between in vivo bladder cancers
(B) and in vitro bladder cancer cells (C) is unlikely due to the difference
between the three-dimensional and two-dimensional cultures. A previ-
ous study comparing two-dimensional and three-dimensional cultures
of mouse embryonic stem cells failed to find any differentially altered
signaling pathways [14].
In the present study, the differentially expressed genes found in vitro
were functionally related to cellular process, cell cycle, cell death, and
differentiation, and those genes found in vivo were related to cell com-
munication and cell adhesion. Moreover, the significantly differentiated
pathways of this syngeneic orthotopic rat bladder cancer model, like the
BBN-induced rat bladder cancer [7] (own unpublished data), corre-
sponded closely with those of muscle-invasive human tumor. Interest-
ingly, the host response pathways, that is, MHC pathways and related
immune cell response pathways, were found to be actually upregulated
in this syngeneic and orthotopic rat bladder cancer model (see also
Arum et al. [5]).
Morphologically, we found that a very small proportion of the tumor
seemed to survive despite being surrounded by inflammatory cells.
Analysis by electron microscopy revealed that these foci of cancer cells
(approximately 20-50 cells) were compact and intimately inter-
connected to each other by a microvillus-formed mesh and that there
was no appearance of angiogenesis within these foci, which was con-
firmed by immunohistochemistry for VEGF. Thus, we propose that
Figure 4. Ultrastructure of rat (A–D) and human (E–H) bladder cancer cells and tissues (asterisks). Note: AY-27 cancer cells in the culture
display microvilli (arrow) (A). Most cancer cells in the bladder (at 3 weeks after inoculation) do not display microvillus-formed mesh (B),
but occasionally, small areas of the cancer cells display microvilli (C). (D) Higher magnification of panel C showing desmosomes (arrows)
connecting cells. Most cancer cells in patients at stage of T2-T4 do not display microvilli (E and F), but occasionally, small areas of the
cancer cells display microvillus-formed mesh (arrow) (G). (H) Higher magnification of panel G showing desmosomes (arrows) connecting
cells. Bar, 500 nm.
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the microvillus-formed mesh may enclose the so-called “CSC niche”
that excludes lymphocyte infiltration and vascularization, creating a
hypoxic and low-nutrient microenviroment within the tumors, thereby
resisting chemotherapy and/or radiotherapy.
The concept of niche biology has been proposed as an attempt to
understand how stem cells that reside in a special ultrastructure (i.e.,
“niche”) reproduce or self-renew [15,16]. It has been suggested that
the niches are composed not only of stem cells but also of a diverse
gathering of neighboring differentiated cell types [17]. It has also
been hypothesized that the stem cell niche may be “hijacked” by
the CSCs for tumor initiation, progression, invasion, metastasis, and
recurrence [18,19]. The present study is certainly not conclusive, but
it does lend evidence in support of our hypothesis that indeed a sub-
population of the cancer cells elude immunosurveillance within the
microvillus-formed niches and that the putative CSCs may be located
within this niche. This is also the case for CSCs as well as CSC niche in
general in that conclusive evidence is still lacking. CSCs have been de-
fined on the basis of their ability to seed tumors in animal hosts, to self-
renew, and to spawn differentiated progeny (non-CSCs) [20,21]. For
instance, a recentNature Medicine article by Gupta et al. has postulated
a novel hypothesis that a dynamic equilibriummay exist between CSCs
and non-CSCs within the tumor microenvironment. Moreover, this
Figure 5. Immunostained photographs of rat bladder cancer with antibodies to PCNA (A), caspase-3 (B), E-selectin (C), L-selectin (D), P-
selectin (E), E-cadherin (F), PGP9.5 (G), VEGF (H), CD3 (I), CD133 in adjacent normal tissue (J), CD133 in tumor tissue (K), CD45RA (L),
Oct-4 in adjacent normal tissue (M), Oct-4 in tumor tissue (N), and nestin (O). The tumors are indicated by asterisks, whereas the adjacent
normal tissues by arrows. Bar, 100 μm.
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equilibrium may be shifted in one direction or another by contextual
signals within the tumor microenvironment that influence the probabil-
ity of interconversion between the CSC and non-CSC compartment
[21]. On the basis of our observations and in consideration of the hy-
pothesis of Gupta et al. [21], we suggest that the microvillus-formed
niche that harbors both CSCs and non-CSCs cells might act as this
compartment and, in effect, prevents tumor eradication by the host
immune system.
The model of the CSC niche proposed in the present study differs
from those of the previous studies that have arisen primarily from stud-
ies in which human tumor cells are transplanted into immunodeficient
mice. It is known that xenotransplantation is problematic because the
growth of tumor cells requires an intricate network of interactions with
diverse support cells (including fibroblasts, endothelial cells, mac-
rophages, mast cells, and mesenchymal stem cells) and many of the
cytokines and receptors required for these two-way interactions are
incompatible between mice and humans. Furthermore, whether many
human tumor cells can home efficiently to an appropriate niche in the
mouse is unclear [16,18,19,22,23]. Figure 6 shows a comparison of
these two CSC niche models. According to the current model
(Figure 6A), anticancer targets include cancer cells per se (not cancer-
specific), CSCs (not available because of lacking biomarkers), angio-
genesis (for large tumors only), adhesion molecules (difficult to increase
adhesion for preventing metastasis), and immune system activation
(compromised immune response after chemotherapy). According to
our model (Figure 6B), the molecular target should be the microvillus-
formed CSC niches. In the present study with immunohistochemistry,
we found E-cadherin, one of cadherins of the desmosomes, and selectins
(including E-, L-, and P-selectins) to be expressed in the epithelia but not
in the tumor and desmoglein1 + 2 to be negative. It will be a great chal-
lenge in the future to identify the specific molecular markers for the
niches, more precisely, the connections, i.e., desmosomes, between the
cancer cells rather than the cancer cells and/or the CSCs per se. It will also
be of interest to investigate in the future whether this microvillus-formed
niche exists in other types of neoplasia. We anticipate that targeting the
tumor microvillus-desmosomes could potentially break the niche, allow-
ing host response cells (e.g., lymphocytes, natural killer cells), angiogen-
esis, and circulating anticancer drugs access to the CSCs, at all stages of
the cancer disease.
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